|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:XYZ_Biotech
|
|
gptkbp:awards
|
Best New Drug 2022
|
|
gptkbp:budget
|
2022
|
|
gptkbp:CEO
|
gptkb:John_Doe
|
|
gptkbp:clinicalTrials
|
gptkb:Australia
gptkb:Canada
gptkb:Germany
gptkb:UK
gptkb:USA
Ongoing
Phase 1
Phase 2
Phase 3 trials
|
|
gptkbp:communityEngagement
|
Local Sponsorships
Health Awareness Campaigns
Employee_Volunteer_Programs
|
|
gptkbp:employees
|
500
Paid Time Off
Retirement Plans
Flexible Work Hours
Health_Insurance
Professional_Development
|
|
gptkbp:founded
|
2001
|
|
gptkbp:founder
|
gptkb:Alice_Johnson
|
|
gptkbp:globalPresence
|
gptkb:Asia
Europe
|
|
gptkbp:headCoach
|
gptkb:Dr._Jane_Smith
|
|
gptkbp:headquarters
|
gptkb:Manhattan
gptkb:New_York,_USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
LMN Pharmaceuticals
|
|
gptkbp:investmentFocus
|
Research Grants
Technology Development
Biotech Startups
Venture_Capital_Group
|
|
gptkbp:market
|
gptkb:North_America
|
|
gptkbp:marketSegment
|
Direct Sales
International Expansion
Digital_Marketing
Patient_Education_Programs
Partnerships_with_Hospitals
|
|
gptkbp:partnerships
|
gptkb:ABC_Research_Institute
|
|
gptkbp:patentCitation
|
20
|
|
gptkbp:philanthropy
|
gptkb:Cancer_Research_Fund
|
|
gptkbp:products
|
Cancer treatment drugs
|
|
gptkbp:regulatoryCompliance
|
FDA_approved
|
|
gptkbp:research_areas
|
Immunology
Neurology
Hematology
|
|
gptkbp:researchAndDevelopment
|
$50 million
|
|
gptkbp:revenue
|
$200 million
|
|
gptkbp:specializesIn
|
Oncology
|
|
gptkbp:stockSymbol
|
LMNP
|
|
gptkbp:subsidiary
|
gptkb:LMN_Biologics
|
|
gptkbp:sustainabilityInitiatives
|
Green Manufacturing
Renewable Energy Use
Waste Reduction Program
|
|
gptkbp:website
|
www.lmnpharma.com
|